false
0001739104
0001739104
2024-01-02
2024-01-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 2, 2024
Elanco
Animal Health Incorporated
(Exact name of registrant as specified
in its charter)
Indiana | |
001-38661 | |
82-5497352 |
(State
or other jurisdiction
of incorporation) | |
(Commission
File Number) | |
(IRS Employer Identification Number) |
2500 Innovation Way
Greenfield, Indiana (Address of principal executive offices)
| |
46140 (Zip
Code) |
Registrant’s telephone number, including area code: (877)
352-6261
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
| ¨ | Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which
registered |
Common stock, no par value |
|
ELAN |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
¨ Emerging
growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 |
Regulation FD Disclosure. |
A copy of the press release issued by Elanco Animal Health Incorporated
(the “Company”) announcing certain planned Board of Director and Committee leadership changes and proposed voting standard
change is attached to this Current Report on Form 8-K as Exhibit 99.1. The information in this Item 7.01, including the information
contained in the accompanying Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section, and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities
Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as otherwise expressly stated in such
filing.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ELANCO ANIMAL HEALTH INCORPORATED |
|
|
Date: January 2, 2024 |
By: |
/s/ Todd Young |
|
Name: Todd Young |
|
Title: Executive Vice President and Chief Financial Officer |
Exhibit 99.1
| Elanco Animal Health
2500 Innovation Way
Greenfield, IN 46140 |
FOR IMMEDIATE RELEASE
Media Contact: Colleen Parr Dekker, +1.317.989.7011, colleen.dekker@elancoah.com
Investor Contact: Kathryn Grissom, +1.317.273.9284, kathryn.grissom@elancoah.com
Elanco Animal Health Announces Planned Board
Leadership Changes and Corporate Governance Actions
Lawrence Kurzius to become next Chairman of
the Board
GREENFIELD, Ind. (January 2, 2024) – Elanco
Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has named Lawrence E. Kurzius as its next Chairman
of the Board, effective at the conclusion of the Company’s 2024 Annual Meeting of Shareholders. Mr. Kurzius, a member of the
Elanco Board since 2018, will succeed current Chairman, R. David Hoover, who will remain on the Board as an independent director.
“It has been a privilege to serve as Chairman of
Elanco’s Board to help guide the Company through its first five years as an independent public company,” said R. David
Hoover. “In that period, we have transformed Elanco into a diversified, durable animal health leader with greater global
scale, a more balanced product mix and a strong omnichannel presence in the pet health industry. The Board has had an intentional
plan to evolve our governance and leadership over time as the Company has matured, including the initiation of our leadership
succession plan which began this past summer. With the standup and the successful integration of Bayer Animal Health behind us and
an exciting future of long-term value creation expected ahead with anticipated blockbuster innovation launches, it is the right time
to execute our plans. We are fortunate to have Lawrence in place to assume the role of Chairman. He has a valuable mix of global
business expertise, brand building insights, a track record of value creation, and significant corporate governance experience. I
look forward to continuing to work closely with him and our colleagues on the Board and management team to guide the Company’s
future success.”
Elanco previously announced its plan to amend the Company’s corporate
governing documents with proposals to be presented at the 2024 Annual Meeting of Shareholders, including beginning a process to declassify
the Board of Directors, providing shareholders the right to amend the Company’s Bylaws and enabling shareholders, under certain
circumstances, to call special meetings. Elanco is also announcing it intends to seek shareholder approval to modify the voting standard
for uncontested director elections from a plurality standard to a majority of votes cast.
Following the 2024 Annual Meeting, the Board plans to rotate committee
leadership with Michael Harrington assuming the role of Chairman of the Corporate Governance Committee and Kirk McDonald serving as Chairman
of the Compensation and Human Capital Committee.
“On behalf of the entire Board, I want to thank Dave for
his dedication to Elanco during his tenure as Chairman,” said Lawrence E. Kurzius. “The Board has benefitted greatly from
Dave’s leadership skills, industry knowledge and financial and strategic acumen, and we expect to continue to benefit from his guidance
as an independent member of our Board.”
Mr. Kurzius continued, “I am honored to be designated as
the next Chairman of the Board. Today’s announcement, including Board and committee leadership rotation and enhanced shareholder
rights, reflects our commitment to robust corporate governance and shareholder engagement. The Board and the Company’s leadership
team remain laser focused on advancing our strategy, and I remain confident in our ability to realize the benefits of our scale, portfolio
diversity, product mix and innovation delivery to drive sustainable growth and long-term value for shareholders.”
About Lawrence E. Kurzius
Lawrence E. Kurzius has served as Executive Chairman of McCormick &
Company, Inc. (NYSE: MKC), a global food company, since 2017. Mr. Kurzius also served as Chief Executive Officer of McCormick
from 2016 to 2023 and President from 2015 to 2022. He held roles of increasing responsibility at the company beginning in 2003, including
President and Chief Operating Officer (from 2015 to 2016), President of the company’s global consumer business (from 2013 to 2016),
Chief Administrative Officer (from 2013 to 2015) and President of EMEA (from 2007 to 2008). Prior to joining McCormick, Mr. Kurzius
served as Chief Executive Officer of Zatarain’s, a spice company, from 1991 to 2003. Earlier in his career, he was a marketing executive
with the Quaker Oats Company and Mars Inc.’s Uncle Ben’s Company. Mr. Kurzius also currently serves on the board of The
Cooper Companies, Inc. (Nasdaq: COO), a global medical device company.
About Elanco
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in
animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating
value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we
are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local
and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™
Sustainability Pledges –all to advance the health of animals, people, and the planet. Learn more at elanco.com.
Forward Looking Statements
This press release may include certain statements concerning expectations
for the future, include expectations for innovation and product launches, that are forward-looking statements as defined by federal securities
law. Such forward-looking statements are subject to a variety of known and unknown risks, uncertainties, and other factors that are difficult
to predict and many of which are beyond management’s control. These risks and assumptions are described in Elanco’s annual
reports on Form 10-K, quarter reports on Form 10-Q and other reports that are available from the U.S. Securities and Exchange
Commission. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect our view only as of the date
made. We undertake no obligation to update any forward-looking statement, except as otherwise required by law.
v3.23.4
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From May 2024 to Jun 2024
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Jun 2023 to Jun 2024